Physician profile
David Christopher Black
NPI 1457324352
$4,125.31
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $490 · 2022: $1,214 · 2023: $1,280 · 2024: $1,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,421.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $526.39 | 2022-2024 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $394.58 | 2021-2024 | |
| Glaxosmithkline, LLC. | $387.03 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $353.44 | 2021-2024 | |
| Exact Sciences Corporation | $302.00 | 2023-2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $282.25 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $260.01 | 2021-2023 | Vraylar |
| Abbott Laboratories | $259.18 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Dexcom, INC. | $214.36 | 2021-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $208.67 | 2021-2024 | Repatha, Otezla, Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $168.85 | 2021-2024 | Xifaxan |
| Amarin Pharma, INC. | $132.89 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.90 | 2022-2024 | Ofev, Jardiance |
| Otsuka America Pharmaceutical, INC. | $82.93 | 2022-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $52.47 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $51.31 | 2022 | |
| Phathom Pharmaceuticals, INC. | $49.95 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $42.77 | 2022-2023 | Farxiga |
| Xeris Pharmaceuticals, INC. | $35.07 | 2022-2024 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $31.42 | 2022 | |
| Sumitomo Pharma America, INC. | $21.65 | 2023 | Gemtesa |
| Ultragenyx Pharmaceutical INC. | $20.57 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.48 | 2022 | |
| Lundbeck LLC | $17.74 | 2021 | |
| Intra-Sana Laboratories | $15.00 | 2021 | |
| Ibsa Pharma INC. | $14.62 | 2022 | |
| Tolmar, INC. | $14.05 | 2024 | |
| Idorsia Pharmaceuticals US INC | $14.02 | 2023 | Quviviq |
| Nabriva Therapeutics, Plc | $13.20 | 2022 | |
| Merck Sharp & Dohme LLC | $12.62 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.